{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:42:21Z","timestamp":1776912141982,"version":"3.51.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The management of hemostasis in patients medicated with apixaban (Eliquis) undergoing emergency cardiac surgery is exceedingly difficult. The body\u2019s natural elimination pathways for apixaban prove ineffective in emergency situations, and the impact of hemodialysis is limited. The application of Cytosorb<jats:sup>\u00ae<\/jats:sup> may attenuate the concentration of apixaban, thereby facilitating the stabilization of these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An 84-year-old man treated with apixaban, underwent emergency ascending aorta replacement surgery due to an acute type A aortic dissection. To address the challenges induced by apixaban, we integrated Cytosorb<jats:sup>\u00ae<\/jats:sup> cartridge into the Cardiopulmonary bypass circuit. There was a 63.7% decrease in perioperative apixaban-specific anti-factor Xa activity. The patient\u2019s postoperative course was favourable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Hemoadsorption with Cytosorb<jats:sup>\u00ae<\/jats:sup> may offers a safe and feasible approach for reducing apixaban concentration in emergency cardiac surgery, thereby mitigating the risk of hemorrhagic complications.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13019-024-02748-1","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T07:01:36Z","timestamp":1712386896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review"],"prefix":"10.1186","volume":"19","author":[{"given":"Vitor","family":"Mendes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaid","family":"Mamode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal","family":"Jolou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mourad","family":"Malki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Ellenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Cikirikcioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"issue":"2","key":"2748_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S1010-7940(01)01099-5","volume":"21","author":"D Paparella","year":"2002","unstructured":"Paparella D. Cardiopulmonary bypass induced inflammation pathophysiology and treatment. An update Eur J Cardio-Thorac Surg. 2002;21(2):232\u201344.","journal-title":"An update. Eur J Cardio-Thorac Surg"},{"issue":"11","key":"2748_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.hlc.2022.07.015","volume":"31","author":"V Naruka","year":"2022","unstructured":"Naruka V, Salmasi MY, Arjomandi Rad A, Marczin N, Lazopoulos G, Moscarelli M, et al. Use of Cytokine Filters During Cardiopulmonary Bypass: Systematic Review and Meta-Analysis. Heart Lung Circ. 2022;31(11):1493\u2013503.","journal-title":"Heart Lung Circ."},{"key":"2748_CR3","unstructured":"CytoSorbents Corporation. CytoSorb\u00ae Assigned Dedicated Procedure Code in Switzerland. In:PRNewswire. 2018.\u00a0Available from: https:\/\/cytosorbents.com\/cytosorb-assigned-dedicated-procedure-code-in-switzerland\/. Cited 2023 Oct 9."},{"key":"2748_CR4","unstructured":"CytoSorbents Corporation. Health Canada Authorizes Cytosorb For Use In Hospitalized COVID-19 Patients. In:PRNewswire. 2021.\u00a0Available from:https:\/\/cytosorbents.com\/health-canada-authorizes-cytosorb-for-use-in-hospitalized-covid-19-patients\/. Cited 2023 Oct 9."},{"issue":"2","key":"2748_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s41669-019-00183-w","volume":"4","author":"M Javanbakht","year":"2020","unstructured":"Javanbakht M, Trevor M, Rezaei Hemami M, Rahimi K, Branagan-Harris M, Degener F, et al. Ticagrelor Removal by CytoSorb\u00ae in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis. Pharmacoecon Open. 2020;4(2):307\u201319.","journal-title":"Pharmacoecon Open."},{"issue":"8","key":"2748_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1177\/0267659120967827","volume":"36","author":"V Mendes","year":"2021","unstructured":"Mendes V, Colombier S, Verdy F, Bechtold X, Schlaepfer P, Scala E, et al. Cytosorb \u00ae hemoadsorption of apixaban during emergent cardio-pulmonary bypass: a case report. Perfusion. 2021;36(8):873\u20135.","journal-title":"Perfusion."},{"issue":"3","key":"2748_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12325-012-0003-2","volume":"29","author":"D Jim\u00e9nez","year":"2012","unstructured":"Jim\u00e9nez D, Yusen RD, Ramacciotti E. Apixaban: an Oral Direct Factor-Xa Inhibitor. Adv Ther. 2012;29(3):187\u2013201.","journal-title":"Adv Ther."},{"issue":"10","key":"2748_CR8","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265\u201379.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"2748_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/hdi.13127","volume":"28","author":"T Poel","year":"2024","unstructured":"Poel T, de Rouw N, P\u00e9qu\u00e9riaux NCV, van de Kerkhof D, Windsant AMAV, van Marum RJ, et al. Effect of conventional hemodialysis on the apixaban plasma concentration. Hemodialysis International. 2024;28(1):72\u20136.","journal-title":"Hemodialysis International."},{"issue":"14","key":"2748_CR10","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2019;380(14):1326\u201335.","journal-title":"New England Journal of Medicine."},{"issue":"2","key":"2748_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/HPC.0000000000000177","volume":"18","author":"N Beik","year":"2019","unstructured":"Beik N, Reddy P, Sylvester KW, Connell NT, Giugliano RP, Piazza G, et al. Andexanet Alfa (Andexxa) Formulary Review. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine. 2019;18(2):66\u201371.","journal-title":"Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine."},{"key":"2748_CR12","first-page":"14","volume":"31","author":"S Wei","year":"2023","unstructured":"Wei S, Zhang Y, Zhai K, Li J, Li M, Yang J, et al. CytoSorb in patients with coronavirus disease 2019: A rapid evidence review and meta-analysis. Front Immunol. 2023;31:14.","journal-title":"Front Immunol."},{"key":"2748_CR13","doi-asserted-by":"crossref","unstructured":"Abraham P, Mendes V, Kirsch M, Schneider A. Hemoperfusion in Cardiac Surgery and ECMO. In: Ronco C, Bellomo R, editors. Contributions to Nephrology Adsorption: The New Frontier in Extracorporeal Blood Purification. S.Karger AG; 2023;180\u201391.\u00a0Available from: https:\/\/karger.com\/doi\/10.1159\/000527338","DOI":"10.1159\/000527338"},{"issue":"6","key":"2748_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1053\/j.jvca.2022.01.038","volume":"36","author":"H R\u00f8ed-Undlien","year":"2022","unstructured":"R\u00f8ed-Undlien H, Schultz NH, Lunnan A, Husebr\u00e5ten IM, Wollmann BM, Molden E, et al. In Vitro Apixaban Removal By CytoSorb Whole Blood Adsorber: An Experimental Study. J Cardiothorac Vasc Anesth. 2022;36(6):1636\u201344.","journal-title":"J Cardiothorac Vasc Anesth."},{"issue":"12","key":"2748_CR15","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/jcpt.13802","volume":"47","author":"M Buonocore","year":"2022","unstructured":"Buonocore M, Rex S, Degezelle K, Meyns B. CytoSorb haemoadsorption for removal of apixaban\u2014A proof-of-concept pilot case for a randomized controlled trial. J Clin Pharm Ther. 2022;47(12):2373\u20135.","journal-title":"J Clin Pharm Ther."},{"issue":"19","key":"2748_CR16","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.3390\/jcm11195889","volume":"11","author":"K Hassan","year":"2022","unstructured":"Hassan K, Thielmann M, Easo J, Kamler M, Wendt D, Haidari Z, et al. Removal of Apixaban during Emergency Cardiac Surgery Using Hemoadsorption with a Porous Polymer Bead Sorbent. J Clin Med. 2022;11(19):5889.","journal-title":"J Clin Med."},{"issue":"1","key":"2748_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13256-023-03949-3","volume":"17","author":"V Dalmastri","year":"2023","unstructured":"Dalmastri V, Angelini A, Minerva V, Ballarini M, Grammatico F, Todeschini P, et al. Extracorporeal hemoadsorption therapy as a potential therapeutic option for rapid removal of Apixaban in high risk-surgical patients: a case report. J Med Case Rep. 2023;17(1):283.","journal-title":"J Med Case Rep."},{"issue":"2","key":"2748_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1751143718772789","volume":"20","author":"V Dhokia","year":"2019","unstructured":"Dhokia V, Madhavan D, Austin A, Morris CG. Novel use of CytosorbTM haemadsorption to provide biochemical control in liver impairment. J Intensive Care Soc. 2019;20(2):174\u201381.","journal-title":"J Intensive Care Soc."}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02748-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-024-02748-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-024-02748-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T07:03:17Z","timestamp":1712386997000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiothoracicsurgery.biomedcentral.com\/articles\/10.1186\/s13019-024-02748-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1186\/s13019-024-02748-1","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since this is a case report, no ethical review board approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}